SCHEMBL21993660

SCHEMBL21993660

CCCC(=O)N(C)c1cccc(C)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 5/20 0.39
P2RX7 Q99572 1/20 0.39
RAB9A P51151 5/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP1A2 P05177 2/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
OPRM1 P35372 1/20 0.37
HSD17B10 Q99714 2/20 0.36
NPC1 O15118 3/20 0.36
MAPT P10636 3/20 0.36
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
PKM P14618 1/20 0.36
GRM5 P41594 2/20 0.36
MAPK1 P28482 1/20 0.36
GBA1 P04062 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13713493 0.87 OPRM1 (0.43) TP53P2RX7RAB9AMEN1KMT2A
SCHEMBL8234459 0.79 P2RX7 (0.38) TP53P2RX7RAB9AMEN1KMT2A
SCHEMBL24864136 0.79 SMN1; SMN2 (0.41) P2RX7RAB9AMEN1KMT2ACYP1A2
SCHEMBL20909909 0.78 RAB9A (0.43) TP53P2RX7RAB9AMEN1KMT2A
SCHEMBL15174120 0.78 RAB9A (0.43) TP53P2RX7RAB9AMEN1KMT2A
SCHEMBL10073737 0.77 ALDH1A1 (0.45) MEN1KMT2AKDM4EALDH1A1HSD17B10
SCHEMBL9665431 0.76 RAB9A (0.42) TP53P2RX7RAB9AMEN1KMT2A
SCHEMBL8278748 0.75 POLQ (0.49) TP53MEN1KMT2ANPC1SMN1; SMN2
SCHEMBL28746527 0.75 NCF1 (0.53) TP53RAB9AMEN1KMT2ACYP1A2
SCHEMBL6946111 0.75 SMN1; SMN2 (0.44) TP53RAB9AMEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11130769-B2 Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein PRELUDE THERAPEUTICS, INCORPORATED (US) 2021-09-28 US disclosed
US-20200148705-A1 Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein PRELUDE THERAPEUTICS, INCORPORATED 2020-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11130769-B2 Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein MCL1, BCL2A1, BCL2L1 TP53 82/4885P2RX7 4489/4885RAB9A 2898/4885
US-20200148705-A1 Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein MCL1, BCL2A1, BCL2L1 TP53 82/4885P2RX7 4489/4885RAB9A 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.